Future heart events such as heart attacks, cardiovascular diseases and strokes can be averted with high doses of statin drugs. But a study shows a number of patients with a risk of heart diseases are not taking the recommended statin drugs.
A two-year follow-up study on 30,000 Medicare patients with heart attack, aged between 66 and 75 years, who received "high-intensity" statin prescription during hospitalization with the heart attack or stroke. The study found.
As statin drugs prevent future risks associated with stroke and heart attacks, heart patients should continue using them with drug dosage prescribed by the physician. Lead author of the study was Professor Robert Rosenson, Icahn School of Medicine, Mount Sinai, New York City and the study was published on April 19, 2017, in the JAMA Cardiology.
In an ongoing research at the University of Alabama shows a reduction in the function of fat or adipose tissue with canagliflozin when compared with glimepiride treatment. The reduction in fat or adipose tissue function is independent of weight loss. The reduction in adipose tissue causes a big impact on changes in energy balance and body metabolism.
Researchers are conducting a CANVAS study between two adult age group of patients with type 2 diabetes (T2D). One group of patients with type 2 diabetes (T2D) are being treated with 300 mg of canagliflozin daily for 52 weeks duration. Similarly, another group of patients with type 2 diabetes (T2D) are being treated with glimepiride (marketed as Amaryl). They observed and analyzed samples for changes in body weight, HbA1c levels and fat or adipose tissue function. At the end of 52 weeks, researchers observed following in canagliflozin (marketed as Invokana) group when compared with glimepiride group.
Lead author of the study was Timothy W Garvey, MD and the study was presented at the American Association of Clinical Endocrinologists (AACE), 26th Annual Scientific and Clinical Congress 2017, held at Austin, Texas, United States. The final results will be declared after the completion of the current CANVAS study.
Glimepiride : Some patients with type 2 diabetes (T2D) could not reduce the levels of blood sugar with diet and physical exercise. Glimepiride treatment, a sulfonylurea antidiabetic medicine is intended to reduce blood sugar or glucose levels in those patients by triggering the pancreas to release insulin.
Adipose tissue : Adipose tissue function is to store excess calories in the form of fat under the skin, around internal organs, breast tissue and bone marrow. This tissue insulates the body too. But its function will be weakened in overweight or obese people, a risk factor to type 2 diabetes (T2D).
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.